within Pharmacolibrary.Drugs.ATC.R;

model R03AK05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AK05</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This is a fixed-dose combination drug composed of reproterol, a short-acting beta-2 adrenergic agonist bronchodilator, and sodium cromoglicate (sodium cromoglycate), a mast cell stabilizer and anti-allergic agent. It has been used in the treatment of asthma and other respiratory conditions such as allergic bronchial asthma. This combination is approved in a limited number of countries for inhalation use in asthma but is not widely available or commonly prescribed currently.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies specifically on the fixed-dose combination product of reproterol and sodium cromoglicate (ATC R03AK05) could be found. Pharmacokinetic estimates below are inferred from individual drug data (inhaled reproterol, inhaled sodium cromoglicate) and not from any combination study or population PK report.</p><h4>References</h4><ol><li><p>Hermann, R, et al., &amp; de Mey, C (1998). Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate. <i>Arzneimittel-Forschung</i> 48(6) 663–667. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9689424/\">https://pubmed.ncbi.nlm.nih.gov/9689424</a></p></li><li><p>Abraham, WM, et al., &amp; Bähre, M (1998). Comparative effects of a fixed combination of reproterol hydrochloride and disodium cromoglycate with each agent alone on antigen-induced airway responses in sheep. <i>Pulmonary pharmacology &amp; therapeutics</i> 11(4) 271–276. DOI:<a href=\"https://doi.org/10.1006/pupt.1998.0150\">10.1006/pupt.1998.0150</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10101743/\">https://pubmed.ncbi.nlm.nih.gov/10101743</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AK05;
